DNBC-FINANCIAL-GROUP
13.4.2022 18:35:14 CEST | Business Wire | Press release
To make a big achievement in today's global economy and win sales against overseas competition, businesses must provide their clients with appealing sales conditions accompanied by proper international business payments mechanisms. The most common way to pay international business invoices is via bank wire transfer or credit unions, yet the currency exchange rate is high.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005543/en/
Another option is believed to be one of the best international payment solutions for business is via online payment providers. DNBC now will show you 5 reasons to make international business payments via business account to avoid losing potential customers to competition by failing to consider other payment choices.
1. Being Transparent
Businessmen are concerned they would be charged high fees if they want to make international business payments. Making cross-border payments may be complicated and costly due to hidden fees and confusing exchange rate calculations. Make sure you always know the exchange rates and costs associated with money transfer services prior to making a transaction.
2. Transferring around the world in multiple currencies
Cash is still preferred when making purchases, but not everyone is willing to accept it, especially when making international business payments. Paying mortgages and other invoices in a foreign nation is a tremendous demand for any businessman.
At DNBC Financial Group
, we enable SWIFT and SEPA transfers to 170 countries and territories worldwide, providing our clients with a range of transfer alternatives at the lowest possible rate and with the least amount of wait time.
3. Organizing Your Business Records
Having a business checking account to make international business payments is a great idea for businessmen to manage their firm. The account may store both receipts and expenditure checks, which helps you keep track of costs, check up on spending, avoid overspending and calculate profit margin in an easy way.
With DNBCnet Mobile App
, you may check the balance on your payment card at any time and from any location through DNBCnet, SMS Banking, or any ATM. Moreover, we also support exporting e-statements of your transactions over the course of a month or many months.
4. Transferring Limits
The maximum amount per transaction is one of the top requirements for creating a business checking account. Some suppliers need a minimum payment, while others have no restrictions at all. Finding a source or provider that can consistently meet your company's demands is critical.
Here at DNBC, the transaction limit can come up to 500 000 EUR/ day for business accounts.
5. Transferring Speed
Since making international business payments via bank transfer requires the person to visit the physical bank and fill out paperwork, it is considered to be extremely time-consuming. Or, when you need an instant transfer, credit unions can be the best bet. However, fees for these services are charged higher than other methods!
Online payment providers like DNBC provide lower transaction costs and the same advantages. It takes one to three business days to process most currencies, but some currencies may take longer. Here is DNBC Financial Group's average transaction speed:
- SWIFT services for international transfer: 02-05 business days
- SEPA for Eurozone transfer: 01-02 business days
Make International Payments Via Business Accounts With DNBC
DNBC Financial Group strives to become the best business account for international payments. We offer full online banking experience, money transactions in over 170 countries with multiple currencies, and are always ready to support you 24/7. Find out how DNBC can help you make international payments better.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005543/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom